Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
20 hedge funds and large institutions have $1.64M invested in Apexigen, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
33% more funds holding
Funds holding: 15 → 20 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $2.16M → $1.64M (-$516K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$180K |
| 2 |
Two Sigma Investments
New York
|
+$34.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$33.8K |
| 4 |
Millennium Management
New York
|
+$26.2K |
| 5 |
Renaissance Technologies
New York
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$17.7K |
| 2 |
Jane Street
New York
|
-$12.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.81K |
APGN Hedge Fund Activity: Q1 2023 in Review
20 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q1 2023, worth a combined $1.64M — down 24% from $2.16M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new APGN positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $180K. The largest seller was Citadel Advisors, exiting entirely with an estimated $17.7K sold.
- 20 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q1 2023, up from 15 in Q4 2022.
- Funds reported $1.64M of Apexigen, Inc. Common Stock stock for Q1 2023, down 24% quarter-over-quarter.
- 7 funds opened new Apexigen, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +5 holders.
- The largest Apexigen, Inc. Common Stock buyer in Q1 2023 was CVI Holdings, an estimated $180K added.
- The largest Apexigen, Inc. Common Stock seller in Q1 2023 was Citadel Advisors, an estimated $17.7K sold.
Based on aggregated 13F filings for Q1 2023.